WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

• Morgan Stanley 23^rd Annual Global Healthcare Conference; the fireside chat will be held at the Sheraton New York Times Square on Tuesday, September 9, 2025 at 5:35 p.m. ET
• H.C. Wainwright 27^th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Wednesday, September 10, 2025 at 9:00 a.m. ET

Webcasts of the fireside chat and presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. Archived replays of the webcasts will be available on the Company’s website for 90 days following the events.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA^™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T^™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
This email address is being protected from spambots. You need JavaScript enabled to view it.

Melissa Forst
Argot Partners
212-600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it.